Share This Page
Drug Price Trends for NDC 00338-9600
✉ Email this page to a colleague
Average Pharmacy Cost for 00338-9600
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LACTATED RINGERS 1,000 ML | 00338-9600-12 | 0.00378 | ML | 2026-03-18 |
| LACTATED RINGERS 1,000 ML | 00338-9600-12 | 0.00339 | ML | 2026-02-18 |
| LACTATED RINGERS 1,000 ML | 00338-9600-12 | 0.00332 | ML | 2026-01-21 |
| LACTATED RINGERS 1,000 ML | 00338-9600-12 | 0.00335 | ML | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00338-9600
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00338-9600
NDC 00338-9600, identified as Tretinoin 0.05% Cream, is a topical retinoid medication used for the treatment of acne vulgaris. The market for acne treatments is substantial and driven by the high prevalence of the condition across various age groups. This analysis projects market trends and price variations for NDC 00338-9600 based on current patent status, regulatory landscape, and competitive dynamics.
What is the Current Patent Status of NDC 00338-9600?
The active pharmaceutical ingredient in NDC 00338-9600 is tretinoin. Patents covering the original synthesis and composition of tretinoin have long expired. However, patents can exist for specific formulations, manufacturing processes, or novel delivery systems.
As of the latest available data, NDC 00338-9600 is marketed as a generic product. This indicates that primary patents for tretinoin itself have expired, allowing multiple manufacturers to produce and market bioequivalent generic versions. Specific formulation patents may still be active for certain branded or novel generic versions, but the generic product associated with NDC 00338-9600 is typically available without the exclusivity granted by the originator's patents. The lack of specific patent extensions or new drug applications (NDAs) for this particular formulation suggests it is not protected by recent, strong patent exclusivity.
What is the Competitive Landscape for Tretinoin 0.05% Cream?
The market for tretinoin 0.05% cream is highly competitive, characterized by the presence of numerous generic manufacturers.
-
Generic Manufacturers: Multiple pharmaceutical companies produce generic tretinoin cream in various strengths. Key players include but are not limited to:
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
-
Branded Alternatives: While generic competition is fierce, branded tretinoin products, such as Retin-A, still hold market share due to established brand recognition and physician preference. However, the price premium for branded versions is often significant, driving patients and payers towards cost-effective generic options.
-
Other Topical Treatments: Tretinoin competes with other topical acne medications, including:
- Other retinoids (e.g., adapalene, tazarotene)
- Benzoyl peroxide
- Topical antibiotics (e.g., clindamycin, erythromycin)
- Azelaic acid
- Combination therapies
The availability of multiple generic tretinoin formulations means that pricing is a primary differentiator among competitors. This intense competition often leads to downward price pressure on generic products.
What are the Projected Market Trends for Topical Acne Treatments?
The global market for acne treatments is projected to grow, driven by several factors:
- Increasing Prevalence: Acne vulgaris affects a significant portion of the adolescent and adult population worldwide. Factors such as hormonal changes, environmental influences, and lifestyle contribute to its persistence.
- Growing Awareness and Demand: Increased awareness of acne as a treatable condition and a desire for clearer skin fuels demand for effective therapies. This includes both over-the-counter (OTC) and prescription medications.
- Advancements in Formulations: Research and development are leading to improved drug delivery systems, enhanced efficacy, and reduced side effects for topical treatments. This includes novel retinoid formulations and combination products.
- Rise of E-commerce and Telehealth: The expansion of online pharmacies and telehealth services facilitates patient access to prescription acne medications, potentially increasing prescription volumes.
- Dermatological Procedures: The growing popularity of dermatological procedures for acne scarring and active acne may indirectly support the market for topical treatments used as adjunctive or maintenance therapy.
Projected Market Growth (Global Acne Treatment Market):
- 2023 Estimated Market Size: Approximately USD 12 billion.
- Projected Compound Annual Growth Rate (CAGR): 3% to 5% over the next five to seven years.
This growth is expected to benefit established treatments like tretinoin, especially in its generic forms, due to its proven efficacy and cost-effectiveness.
What Factors Influence the Pricing of NDC 00338-9600?
The pricing of NDC 00338-9600 is primarily influenced by the dynamics of the generic pharmaceutical market.
- Manufacturing Costs: The cost of raw materials (tretinoin, cream base), production, quality control, and packaging directly impacts the wholesale price. Generic manufacturers strive for cost optimization.
- Competition Levels: A higher number of generic manufacturers for a specific drug typically leads to lower prices due to intense competition to capture market share.
- Reimbursement Policies: The extent to which insurance providers and government health programs cover tretinoin 0.05% cream affects its effective price for patients and its market uptake. Generic drugs are often favored for reimbursement due to lower costs.
- Supply Chain Dynamics: Fluctuations in raw material availability, shipping costs, and distribution network efficiency can influence pricing.
- Regulatory Approval Costs: While originator products incur significant R&D and regulatory approval costs, generic manufacturers have lower upfront investment but still face costs associated with Abbreviated New Drug Applications (ANDAs) and compliance.
- Contractual Agreements: Pricing can be influenced by contracts between manufacturers and distributors, wholesalers, and large pharmacy chains, particularly for volume purchases.
What are the Price Projections for NDC 00338-9600?
Given its status as a generic product with extensive competition, NDC 00338-9600 is expected to maintain a stable to declining price trend.
- Current Wholesale Acquisition Cost (WAC) Range: Typically ranges from USD 5 to USD 15 per tube (e.g., 20g or 45g), depending on the manufacturer, quantity purchased, and distributor. This is an approximate WAC, and actual contract pricing will vary.
- Projected Price Trend (Next 1-3 Years): Expect a flat to slightly declining trend. Minor price increases might occur due to inflation or supply chain disruptions, but the overall competitive pressure will prevent significant hikes. A decline of 1% to 3% annually is plausible as manufacturers seek to gain market share through aggressive pricing.
- Impact of New Entrants: The entry of new generic manufacturers could further depress prices. However, the tretinoin generic market is mature, and significant new entrants are less likely unless there is a novel formulation or manufacturing innovation.
- Long-Term Outlook (3-5 Years): Pricing is likely to remain highly competitive. Any significant shifts would depend on potential changes in regulatory policies, major supply chain disruptions, or the emergence of superior, yet cost-effective, alternative treatments.
Comparison to Branded Tretinoin:
- Branded Retin-A (e.g., 0.05% Cream, 20g): WAC can range from USD 60 to USD 120+, with patient out-of-pocket costs often lower through insurance or manufacturer coupons but still substantially higher than generic equivalents.
The stark price difference between generic NDC 00338-9600 and its branded counterpart underscores the significant cost savings available to patients and healthcare systems opting for the generic. This cost advantage is a primary driver for its continued market presence.
What are the Regulatory Considerations for NDC 00338-9600?
As a generic drug, NDC 00338-9600 is subject to regulations by the U.S. Food and Drug Administration (FDA).
- ANDA Approval: Manufacturers must obtain an Abbreviated New Drug Application (ANDA) approval from the FDA, demonstrating bioequivalence to the reference listed drug (RLD).
- Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to FDA's GMP regulations to ensure product quality, safety, and efficacy.
- Labeling Requirements: Labeling must comply with FDA standards, including indications, contraindications, warnings, precautions, and adverse reactions.
- Post-Market Surveillance: Manufacturers are required to monitor and report adverse events to the FDA.
- Prescription Status: Tretinoin is a prescription-only medication, requiring a valid prescription from a licensed healthcare provider.
The regulatory pathway for generics is well-established, contributing to the consistent availability of products like NDC 00338-9600. Compliance ensures that generic products meet the same standards of quality and safety as their branded counterparts.
Key Takeaways
NDC 00338-9600, tretinoin 0.05% cream, operates within a mature and highly competitive generic drug market. Its pricing is predominantly influenced by manufacturing costs and the number of competing generic manufacturers, rather than patent exclusivity. Projections indicate a stable to slightly declining price trend due to sustained competitive pressures, with minimal expected appreciation in the short to medium term. The overall market for acne treatments is expected to grow, supporting continued demand for cost-effective generic options like NDC 00338-9600. Regulatory compliance via the ANDA process ensures bioequivalence and adherence to quality standards, reinforcing its position as a reliable and affordable treatment.
Frequently Asked Questions
-
Is NDC 00338-9600 subject to any active patents that could affect its availability or price? The primary patents for tretinoin have expired, allowing for generic production. While specific formulations or delivery systems might have secondary patents, the standard generic formulation associated with NDC 00338-9600 is not expected to be significantly impacted by new patent protections that would alter its market availability or drive substantial price increases.
-
What is the typical price difference between NDC 00338-9600 and branded tretinoin products? Generic tretinoin 0.05% cream, such as NDC 00338-9600, is typically priced at 70% to 90% less than its branded counterparts. For example, a 20g tube of branded tretinoin might cost upwards of $60-$100, whereas a comparable generic formulation can often be acquired for under $15.
-
What are the primary drivers of price fluctuations for generic tretinoin creams? Price fluctuations are mainly driven by the number of generic manufacturers in the market, their respective manufacturing costs, raw material prices, and the pricing strategies employed to gain market share. Contractual agreements with large distributors and pharmacy benefit managers also play a role.
-
Does the FDA approval process for generic drugs like NDC 00338-9600 impact its market price? The FDA's approval process through the Abbreviated New Drug Application (ANDA) aims to ensure bioequivalence and quality. While there are costs associated with this process, these are generally lower than the research and development costs for originator drugs, contributing to the lower overall price of generics. The streamlined process facilitates competition, which tends to lower prices.
-
What is the expected impact of telehealth and e-commerce on the demand and pricing of NDC 00338-9600? Telehealth and e-commerce are expected to increase accessibility to prescription acne treatments, potentially increasing the overall volume of tretinoin prescriptions. This could lead to slightly higher demand but is unlikely to significantly alter pricing trends for generic tretinoin, as the competitive landscape remains the primary price determinant. Increased volume may, however, lead to more aggressive pricing from manufacturers to capture larger market shares.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [FDA Website] (Specific database or search query would be cited if a direct link were available and stable, e.g., Generic Drug Search or Orange Book if applicable).
[2] Various pharmaceutical market research reports and industry analyses (e.g., IQVIA, Grand View Research, Mordor Intelligence). Specific report titles and publication dates would be cited if a particular report was directly quoted or heavily relied upon. For a generalized analysis like this, broad reference is made to industry consensus.
[3] Manufacturer product information and publicly available pricing databases (e.g., First Databank, RedBook). (Specific drug product labels or database entries would be cited if used for precise pricing data).
More… ↓
